Last Updated : December 3, 2023
CADTH is establishing a time-limited industry task force to identify opportunities and barriers for using industry real-world data (RWD) in our Post-Market Drug Evaluation (PMDE) Program, building upon the recently released Guidance for Reporting Real-World Evidence.
This group is task-oriented and will work collaboratively to develop a summary report for CADTH. This report will advise on best practices and potential approaches for using industry RWD as well as identify ways to mitigate risks and barriers. The summary report will include proposed approaches that will be considered by the PMDE Advisory Committee and CADTH. CADTH intends to share information about the industry task force and the options paper with its stakeholders.
Membership |
||
|---|---|---|
Facilitator |
||
| Don Husereau | Adjunct Professor, University of Ottawa, SEPH | |
Industry Representatives |
||
| Véronique Gaudet | Field Medical Advisor, Bausch Health | |
| Virginie Giroux (Industry Lead) | Director, Health Economic and Outcomes Research, Merck | |
| Jennifer Glass | RWE Lead Canada, Eli Lilly | |
| Nikolas Goyert-Stephens | Senior Manager, Market Access, Biogen | |
| Jason Lee | Head of Market Access and Stakeholder Relations, Amylyx | |
| Maria Luckevich | Health Economics Associate Director, Novo Nordisk | |
| Kevin Pollock | Director of Real-World Evidence, International Markets, Bristol Myers Squibb | |
| Subra Seshadri | Manager Access for Anti-Virals and Hospital Business, Pfizer | |
| Jefferson Tea | Vice-President Medical and Scientific Affairs, Takeda | |
| Jennifer Wu | Health Data Strategy Lead, Roche | |
Health Canada |
||
| Kelly Robinson | Director General, Marketed Health Products Directorate, Health Canada | |
CADTH Representatives |
||
| Tarry Ahuja (CADTH Lead) | Director, Post-Market Drug Evaluation | |
| Trish Caetano | Director, Drug Data Services and Analytics | |
| Peter Dyrda | Director, Pharmaceutical Policy and HTA | |
| Farah Husein | Director, Science and Methods | |
| Brendan McIntosh | Drug Program Advisor, Pharmaceutical Reviews | |
| David Stock | Scientific Advisor, Post-Market Drug Evaluation | |
| Nadine Sulatycky | Program Lead, Post-Market Drug Evaluation | |
Meeting Schedule
The task force will meet monthly initially for 5 to 6 months:
- Meeting 1: September 26, 2023
- Meeting 2: October 24, 2023
- Meeting 3: November 28, 2023
- Meeting 4: January 16, 2024
- Potential meeting 5: To be confirmed
Meeting Summaries
Meeting summaries and the final summary document will be made publicly available. Please check back for regular updates.
Last Updated : December 3, 2023